SEC Form 4 · accession 0000899243-16-019676
Aegerion Pharmaceuticals, Inc. · AEGR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Benjamin Harshbarger
Officer — Acting General Counsel
Period of report
May 9, 2016
Accepted (ET)
May 11, 2016 · 4:03 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001338042
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitsF1,F2 | — | May 9, 2016 | A | 5,100 | A | — | — | Common Stock | 5,100 | 5,100 | D |
| Restricted Stock UnitsF1,F3 | — | May 9, 2016 | A | 7,300 | A | — | — | Common Stock | 7,300 | 7,300 | D |
Explanation of responses
- F1Each restricted stock unit represents a contingent right to receive one share of common stock.
- F2The restricted stock units will vest in three annual installments, with 33.34% of the units vesting on May 9, 2017, 33.33% of the units vesting on May 9, 2018, and 33.33% of the units vesting on May 9, 2019, subject, with limited exceptions, to the Reporting Person's continued employment with the Issuer.
- F3The restricted stock units will vest in three annual installments, with 25% of the units vesting on May 9, 2017, 50% of the units vesting on May 9, 2018, and 25% of the units vesting on May 9, 2019, subject, with limited exceptions, to the Reporting Person's continued employment with the Issuer.